Shots:

• The P-III (KEYNOTE-775/Study 309) trial evaluates Keytruda (200mg, IV, q3w) + Lenvima (20mg, PO, qd) vs doxorubicin (60mg/m2, q3w) or paclitaxel (80mg/m2, q3w) in a ratio (1:1) in 827 patients with EC prior treated with 1 Pt-based CT regimen in any setting including neoadjuvant & adjuvant settings
• The results showed improvements in the 1EPs of OS & PFS over CT while ORR data & additional efficacy & safety data including subgroup analyses are also presented. The results were published in the NEJM
• Keytruda + Lenvima has been approved in the US, EU & Japan for advanced EC. The combination is being evaluated in 20+ clinical trials through a LEAP program in 10+ multiple tumor types

Ref: Merck | Image: Merck